SummitTX Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.87M Sell
99,716
-41,081
-29% -$830K 0.05% 355
2026
Q2
$3.08M Buy
140,797
+74,457
+112% +$1.55M 0.08% 264
2026
Q1
$1.55M Buy
66,340
+27,213
+70% +$591K 0.05% 352
2025
Q4
$822K Sell
39,127
-61,459
-61% -$1.07M 0.02% 444
2025
Q3
$1.55M Sell
100,586
-110,658
-52% -$1.45M 0.06% 306
2025
Q2
$1.98M Buy
211,244
+47,011
+29% +$517K 0.09% 251
2025
Q1
$2.02M Buy
+164,233
New +$2.32M 0.09% 247

Other funds holding SNDX

SummitTX Capital's SNDX Position: Q3 2026 in Review

SummitTX Capital reduced its Syndax Pharmaceuticals (SNDX) stake by 29% in Q3 2026, selling an estimated $830K and leaving 99,716 shares worth $1.87M. The position accounts for 0.05% of the portfolio, ranked #355.

SummitTX Capital first reported a position in SNDX in Q1 2025 and has held it in 7 quarters since. The position peaked at $3.08M in Q2 2026. 237 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

  • SummitTX Capital held 99,716 shares of Syndax Pharmaceuticals worth $1.87M as of Q3 2026.
  • SummitTX Capital sold 41,081 Syndax Pharmaceuticals shares in Q3 2026, an estimated $830K.
  • Syndax Pharmaceuticals made up 0.05% of SummitTX Capital's portfolio in Q3 2026, its #355 holding.
  • SummitTX Capital first reported a position in Syndax Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • SummitTX Capital's Syndax Pharmaceuticals position peaked at $3.08M in Q2 2026.
  • 237 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on SummitTX Capital's 13F filing for Q3 2026, filed 16 Nov 2026.